I guess GSK would not want to make it three in a row after the Ribena fiasco and in yesterday's Australian under heading Glaxo bleeds $18bn ' Dr Steven Nissen the man responsible for wiping $18.2b off GSK market value last week after one of his studies revealed that Glaxo's popular diabetes drug Avandia, may increase heart attack risks.
GSK shares ukp13.33 down ukp1.31
